These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 34830391)
1. (De)stabilization of Alpha-Synuclein Fibrillary Aggregation by Charged and Uncharged Surfactants. Loureiro JA; Andrade S; Goderis L; Gomez-Gutierrez R; Soto C; Morales R; Pereira MC Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830391 [TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646 [TBL] [Abstract][Full Text] [Related]
3. Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC. Palazzi L; Fongaro B; Leri M; Acquasaliente L; Stefani M; Bucciantini M; Polverino de Laureto P Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199427 [TBL] [Abstract][Full Text] [Related]
4. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Conway KA; Harper JD; Lansbury PT Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204 [TBL] [Abstract][Full Text] [Related]
5. Covalent α-synuclein dimers: chemico-physical and aggregation properties. Pivato M; De Franceschi G; Tosatto L; Frare E; Kumar D; Aioanei D; Brucale M; Tessari I; Bisaglia M; Samori B; de Laureto PP; Bubacco L PLoS One; 2012; 7(12):e50027. PubMed ID: 23272053 [TBL] [Abstract][Full Text] [Related]
6. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782 [TBL] [Abstract][Full Text] [Related]
7. Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α-synuclein aggregation. Flagmeier P; Meisl G; Vendruscolo M; Knowles TP; Dobson CM; Buell AK; Galvagnion C Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10328-33. PubMed ID: 27573854 [TBL] [Abstract][Full Text] [Related]
8. Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties. Ulrih NP; Barry CH; Fink AL Biochim Biophys Acta; 2008 Oct; 1782(10):581-5. PubMed ID: 18692132 [TBL] [Abstract][Full Text] [Related]
9. Evidence for Intramolecular Antiparallel Beta-Sheet Structure in Alpha-Synuclein Fibrils from a Combination of Two-Dimensional Infrared Spectroscopy and Atomic Force Microscopy. Roeters SJ; Iyer A; Pletikapić G; Kogan V; Subramaniam V; Woutersen S Sci Rep; 2017 Jan; 7():41051. PubMed ID: 28112214 [TBL] [Abstract][Full Text] [Related]
10. The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Fares MB; Ait-Bouziad N; Dikiy I; Mbefo MK; Jovičić A; Kiely A; Holton JL; Lee SJ; Gitler AD; Eliezer D; Lashuel HA Hum Mol Genet; 2014 Sep; 23(17):4491-509. PubMed ID: 24728187 [TBL] [Abstract][Full Text] [Related]
11. Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation. Bickle L; Hopwood JJ; Karageorgos L Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):261-273. PubMed ID: 28007442 [TBL] [Abstract][Full Text] [Related]
12. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Li J; Uversky VN; Fink AL Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511 [TBL] [Abstract][Full Text] [Related]
13. Structural remodeling during amyloidogenesis of physiological Nα-acetylated α-synuclein. Gallea JI; Sarroukh R; Yunes-Quartino P; Ruysschaert JM; Raussens V; Celej MS Biochim Biophys Acta; 2016 May; 1864(5):501-10. PubMed ID: 26845568 [TBL] [Abstract][Full Text] [Related]
14. Role of Sporadic Parkinson Disease Associated Mutations A18T and A29S in Enhanced α-Synuclein Fibrillation and Cytotoxicity. Kumar S; Jangir DK; Kumar R; Kumari M; Bhavesh NS; Maiti TK ACS Chem Neurosci; 2018 Feb; 9(2):230-240. PubMed ID: 28841377 [TBL] [Abstract][Full Text] [Related]
16. Physicochemical characterization of the G51D mutation of α-synuclein that is responsible for its severe cytotoxicity. Murata T; Tochio N; Utsunomiya-Tate N Neurosci Lett; 2021 Aug; 760():136077. PubMed ID: 34161822 [TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Olanow CW; Brundin P Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095 [TBL] [Abstract][Full Text] [Related]
18. Methionine oxidation in α-synuclein inhibits its propensity for ordered secondary structure. Ponzini E; De Palma A; Cerboni L; Natalello A; Rossi R; Moons R; Konijnenberg A; Narkiewicz J; Legname G; Sobott F; Mauri P; Santambrogio C; Grandori R J Biol Chem; 2019 Apr; 294(14):5657-5665. PubMed ID: 30755483 [TBL] [Abstract][Full Text] [Related]
19. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations. Sahay S; Ghosh D; Singh PK; Maji SK Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727 [TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of the aggregation behavior of alpha- and beta-synuclein. Rivers RC; Kumita JR; Tartaglia GG; Dedmon MM; Pawar A; Vendruscolo M; Dobson CM; Christodoulou J Protein Sci; 2008 May; 17(5):887-98. PubMed ID: 18436957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]